PRISTIQ Drug Patent Profile

When do Pristiq patents expire, and when can generic versions of Pristiq launch?

Pristiq is a drug marketed by Pf Prism Cv and is included in one NDA. There is one patent protecting this drug and two Paragraph IV challenges.

This drug has twenty-two patent family members in sixteen countries.

The generic ingredient in PRISTIQ is desvenlafaxine succinate. There are sixteen drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the desvenlafaxine succinate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Pristiq

A generic version of PRISTIQ was approved as desvenlafaxine succinate by ALEMBIC on June 29^th, 2015.

Summary for PRISTIQ

International Patents:	22
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	46
Clinical Trials:	23
Patent Applications:	45
Drug Prices:	Drug price information for PRISTIQ
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for PRISTIQ
What excipients (inactive ingredients) are in PRISTIQ?	PRISTIQ excipients list
DailyMed Link:	PRISTIQ at DailyMed

See drug prices for PRISTIQ

See drug sales revenues for PRISTIQ

Recent Clinical Trials for PRISTIQ

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Institute of Mental Health (NIMH)	Phase 4
David Steffens	Phase 4
Korea Cancer Center Hospital	Phase 4

See all PRISTIQ clinical trials

Pharmacology for PRISTIQ

Drug Class	Serotonin and Norepinephrine Reuptake Inhibitor
Mechanism of Action	Cytochrome P450 2D6 Inhibitors Norepinephrine Uptake Inhibitors Serotonin Uptake Inhibitors

Paragraph IV (Patent) Challenges for PRISTIQ

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
PRISTIQ	Extended-release Tablets	desvenlafaxine succinate	25 mg	021992	1	2015-05-08
PRISTIQ	Extended-release Tablets	desvenlafaxine succinate	50 mg and 100 mg	021992	12	2012-02-29

US Patents and Regulatory Information for PRISTIQ

PRISTIQ is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pf Prism Cv	PRISTIQ	desvenlafaxine succinate	TABLET, EXTENDED RELEASE;ORAL	021992-003	Aug 20, 2014	AB	RX	Yes	No	8,269,040			Y
Pf Prism Cv	PRISTIQ	desvenlafaxine succinate	TABLET, EXTENDED RELEASE;ORAL	021992-001	Feb 29, 2008	AB	RX	Yes	No	8,269,040			Y
Pf Prism Cv	PRISTIQ	desvenlafaxine succinate	TABLET, EXTENDED RELEASE;ORAL	021992-002	Feb 29, 2008	AB	RX	Yes	Yes	8,269,040			Y

Expired US Patents for PRISTIQ

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pf Prism Cv	PRISTIQ	desvenlafaxine succinate	TABLET, EXTENDED RELEASE;ORAL	021992-002	Feb 29, 2008	7,291,347
Pf Prism Cv	PRISTIQ	desvenlafaxine succinate	TABLET, EXTENDED RELEASE;ORAL	021992-003	Aug 20, 2014	6,673,838
Pf Prism Cv	PRISTIQ	desvenlafaxine succinate	TABLET, EXTENDED RELEASE;ORAL	021992-002	Feb 29, 2008	6,673,838
Pf Prism Cv	PRISTIQ	desvenlafaxine succinate	TABLET, EXTENDED RELEASE;ORAL	021992-001	Feb 29, 2008	7,291,347

International Patents for PRISTIQ

See the table below for patents covering PRISTIQ around the world.

Country	Patent Number	Title	Estimated Expiration
Cyprus	1108202
Austria	397581
Germany	60221642
Spain	2290281

Market Dynamics and Financial Trajectory for the Pharmaceutical Drug: PRISTIQ

Last updated: November 20, 2025

---

Introduction

Pristiq (desvenlafaxine) is a serotonin-norepinephrine reuptake inhibitor (SNRI), primarily prescribed for the treatment of major depressive disorder (MDD). Approved by the U.S. Food and Drug Administration (FDA) in 2009, it falls into a competitive class of antidepressants that play a critical role in mental health management. Analyzing its market dynamics and financial trajectory involves understanding factors such as formulation, patent status, competitive landscape, regulatory environment, and evolving prescribing practices. This review synthesizes these elements to forecast future market trends and financial outcomes for Pristiq.

---

Market Overview and Competitive Position

Product Profile and Therapeutic Context

Pristiq is indicated for the treatment of major depressive disorder, a prevalent condition affecting an estimated 264 million people globally, according to the World Health Organization (WHO). The drug is appreciated for its once-daily oral administration and relatively favorable side effect profile compared to older antidepressants. Its active ingredient, desvenlafaxine, is a pharmacologically optimized metabolite of venlafaxine (Effexor), offering an alternative for patients who tolerate one but not the other.

Market Penetration and Peak Sales

At its launch, Pristiq positioned itself as a novel SNRI with distinct pharmacokinetics. The drug’s peak worldwide sales were approximately $735 million in 2013 according to Evaluate Pharma estimates, but sales tapered over subsequent years. Patent protection, regulatory changes, and increased generic competition substantially influenced its revenue trajectory. In the US, its top-selling years ranged between 2012 and 2014, with notable declines afterward, reflecting the typical post-patent expiry impact seen across pharmacotherapies.

---

Patent Landscape and Generic Competition

Patent Expiry and Biosimilar Entry

Patents granted for Pristiq began expiring in the United States around 2018–2020. The primary U.S. patent, which protected the formulation’s specific dosage and method of use, expired in 2018, allowing generic versions of desvenlafaxine to enter the market. The decreased exclusivity significantly eroded Pristiq’s revenue potential in key markets.

The entrance of generics—embodied by companies like Mylan and Teva—prompted a sharp decline in brand sales. As of 2023, generic desvenlafaxine holds a dominant market share, with brand Pristiq's prescriptions almost obsolescent outside niche uses.

Regulatory and Market Barriers

Despite patent expirations, brand manufacturers have employed strategies such as patent settlements, additional formulation patents, and secondary patents to delay generic entry in certain regions, extending the product’s revenue window marginally. Nonetheless, these tactics have limited success against market forces pushing for lower-cost generics.

---

Market Dynamics

Pricing and Reimbursement Factors

Genericization led to a significant price reduction—often over 80%—making desvenlafaxine a cost-effective alternative for insurers and healthcare providers. Reimbursement policies favor generic prescribing, further diminishing Pristiq’s market share and revenue prospects. This price pressure, combined with the dose flexibility of generics, centralizes market volume among lower-cost competitors.

Prescribing Trends and Therapeutic Shifts

While Pristiq remains prescribed for MDD, its share of the antidepressant market has declined owing to several factors:

• Competitive Alternatives: Other SSRIs and SNRIs, such as escitalopram (Lexapro), duloxetine (Cymbalta), and newer agents, have gained favor owing to efficacy, tolerability, or perceived safety profiles.
• Emerging Therapies: Advances in pharmacotherapy, including augmentation strategies and non-pharmacologic interventions, influence persistent prescribing patterns. Moreover, robust evidence supporting alternative drugs dilutes Pristiq’s market dominance.
• Off-Label Use and Diversification: Pristiq’s off-label use remains limited; however, ongoing research into related indications could influence its utilization landscape.

Regulatory and Reimbursement Dynamics

Insurance formularies increasingly favor generics; branded Pristiq witnessed decreased formulary coverage, favoring cheaper alternatives. The US’s Medicaid program, alongside private payers, has prioritized cost-efficiency, further marginalizing Pristiq’s market share. Regulatory environments promoting biosimilar entry globally will likely accelerate overall generic penetration.

---

Financial Trajectory and Forecast

Historical Revenue Trends

Once a blockbuster, Pristiq's revenues have declined sharply since 2014, attributed chiefly to patent expiry and market saturation with generics. For Eli Lilly and its former licensing partners, the drug served as a substantial revenue stream in its prime years (2011–2014). Post-2018, sales plummeted, with estimates showing multiple-fold reductions.

Forecasting Future Revenues

Given current dynamics, the following trajectory is projected:

• Short-Term (Next 2–3 years): Minimal brand sales, primarily residual prescriptions among select patient groups resistant or tolerant to generic options.
• Medium-Term (3–5 years): Continued erosion of brand value; potential sales only from niche markets or combination therapy indications.
• Long-Term (beyond 5 years): Likely negligible, barring new indications or formulations. The focus shifts to pipeline developments or licensing agreements that could rejuvenate interest.

Potential for Lifecycle Extension or Reformulation

The prospects for growth may hinge on the development of:

• Extended-release formulations with differentiated pharmacokinetics.
• New indications, such as anxiety disorders or chronic pain, where SNRI efficacy is noted.
• Combination therapies integrating desvenlafaxine with other agents to target resistant depression.

Absent such innovations, Pristiq’s financial health will decline monotonically, aligning with the typical life cycle of branded pharmaceutical products post-patent expiry.

---

Strategic Implications for Stakeholders

For pharmaceutical companies holding rights to Pristiq, focus should be on:

• Managing patent protections and launching reformulations or new delivery mechanisms.
• Diversifying into high-growth markets outside traditional antidepressant indications.
• Licensing or partnering to explore additional therapeutic pathways.

Healthcare payers and providers, meanwhile, will continue emphasizing cost-effective generics over branded medications like Pristiq.

---

Key Takeaways

• Market decline is inevitable for branded Pristiq due to patent expiration and accelerated generic competition, leading to significant revenue erosion.
• Pricing pressures and formulary biases favor generics, diminishing Pristiq’s market share rapidly post-patent expiry.
• Future revenue streams are limited, hinging on reformulation or new indications, which are speculative without ongoing clinical trials or regulatory approvals.
• Strategic focus should shift toward pipeline development, patent extensions, or lifecycle management to sustain revenue.
• Stakeholders need to monitor regulatory developments across markets, as biosimilar and biosimilar-like entries accelerate global generic penetration.

---

FAQs

1. When did Pristiq originally receive FDA approval, and how did that impact its market debut?
Pristiq was approved by the FDA in 2009, immediately establishing its presence as a novel SNRI for depression, with initial peak sales supporting its status as a blockbuster.

2. How has patent expiration affected Pristiq’s commercial prospects?
Patent expiration around 2018 led to immediate and sharp declines in sales, as generic desvenlafaxine entered the market, offering similar efficacy at lower prices.

3. What are future growth prospects for Pristiq considering current market conditions?
Long-term prospects are bleak unless the pharmaceutical patent holder develops new formulations or secures new indications; otherwise, the drug is expected to be phased out due to generic competition.

4. Are there any ongoing clinical developments for Pristiq?
To date, no significant new clinical developments aim to extend Pristiq’s lifecycle directly; focus remains on generics and alternative therapies for depression.

5. How do insurance companies influence the market trajectory of drugs like Pristiq?
Insurers tend to favor cost-effective generics, reducing coverage for branded drugs like Pristiq, thus accelerating revenue decline for the original product.

---

References

[1] Evaluate Pharma, "Top Selling Drugs," 2023.
[2] WHO, "Depression Fact Sheet," 2022.
[3] FDA, "Drug Approvals and Patent Expiries," 2018.
[4] IMS Health (now IQVIA), "Pharmaceutical Market Reports," 2022.
[5] Pharmaceutical Patent Watch, "Patent Data for Desvenlafaxine," 2021.